Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

ALKS Alkermes plc

Price (delayed)

$29.9

Market cap

$4.93B

P/E Ratio

13.91

Dividend/share

N/A

EPS

$2.15

Enterprise value

$4.6B

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by ...

Highlights
The debt has plunged by 80% YoY
The company's equity rose by 20% YoY and by 3.2% QoQ
Alkermes's net income has decreased by 19% YoY and by 3.9% from the previous quarter
The EPS has declined by 18% year-on-year and by 3.2% since the previous quarter

Key stats

What are the main financial stats of ALKS
Market
Shares outstanding
164.9M
Market cap
$4.93B
Enterprise value
$4.6B
Valuations
Price to earnings (P/E)
13.91
Price to book (P/B)
3.22
Price to sales (P/S)
3.23
EV/EBIT
10.56
EV/EBITDA
9.93
EV/Sales
3.04
Earnings
Revenue
$1.51B
Gross profit
$1.28B
Operating income
$391.12M
Net income
$352.71M
EBIT
$435.98M
EBITDA
$463.88M
Free cash flow
$581.27M
Per share
EPS
$2.15
EPS diluted
$2.08
Free cash flow per share
$3.56
Book value per share
$9.3
Revenue per share
$9.26
TBVPS
$12.23
Balance sheet
Total assets
$2.08B
Total liabilities
$570.39M
Debt
$74.1M
Equity
$1.51B
Working capital
$1.04B
Liquidity
Debt to equity
0.05
Current ratio
3.33
Quick ratio
2.71
Net debt/EBITDA
-0.7
Margins
EBITDA margin
30.6%
Gross margin
84.4%
Net margin
23.3%
Operating margin
25.8%
Efficiency
Return on assets
16.6%
Return on equity
25.4%
Return on invested capital
31.4%
Return on capital employed
26.6%
Return on sales
28.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALKS stock price

How has the Alkermes stock price performed over time
Intraday
0%
1 week
-2.06%
1 month
7.13%
1 year
25.89%
YTD
3.96%
QTD
-9.45%

Financial performance

How have Alkermes's revenue and profit performed over time
Revenue
$1.51B
Gross profit
$1.28B
Operating income
$391.12M
Net income
$352.71M
Gross margin
84.4%
Net margin
23.3%

ALKS financials

Alkermes's net income has decreased by 19% YoY and by 3.9% from the previous quarter
Alkermes's operating income has decreased by 16% YoY and by 7% from the previous quarter
Alkermes's gross profit has decreased by 13% YoY and by 2.6% from the previous quarter
The revenue has contracted by 12% YoY and by 2.8% from the previous quarter

Price vs fundamentals

How does ALKS's price correlate with its fundamentals

ALKS Price vs fundamentals

ALKS Earnings waterfall

ALKS Price vs fair value

Growth

What is Alkermes's growth rate over time

ALKS growth chart

Valuation

What is Alkermes stock price valuation
P/E
13.91
P/B
3.22
P/S
3.23
EV/EBIT
10.56
EV/EBITDA
9.93
EV/Sales
3.04

Valuation vs average

Price to earnings (P/E)

The EPS has declined by 18% year-on-year and by 3.2% since the previous quarter

Price to book (P/B)

The company's equity rose by 20% YoY and by 3.2% QoQ
The P/B is 11% lower than the 5-year quarterly average of 3.6 and 5% lower than the last 4 quarters average of 3.4

Price to sales (P/S)

The revenue has contracted by 12% YoY and by 2.8% from the previous quarter
ALKS's P/S is 4.2% above its last 4 quarters average of 3.1 but 2.1% below its 5-year quarterly average of 3.3

Efficiency

How efficient is Alkermes business performance
The ROS is up by 35% year-on-year but it has declined by 2.7% since the previous quarter
The return on equity has declined by 26% year-on-year and by 8% since the previous quarter
The ROIC has increased by 22% YoY
The ROA fell by 17% YoY and by 3.5% QoQ

Dividends

What is ALKS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALKS.

Financial health

How did Alkermes financials performed over time

Assets vs liabilities

The company's total liabilities fell by 34% YoY and by 3.4% QoQ
ALKS's quick ratio is up by 17% year-on-year and by 11% since the previous quarter

Debt vs equity

The debt is 95% less than the equity
The debt to equity has plunged by 83% YoY
The debt has plunged by 80% YoY

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.